Discovery

Non-Small-Cell Lung Cancer (NSCLC) Pipeline Landscape Report 2024: Comprehensive Insights About 100+ Companies and 120+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024
Pharmaceutical, Health, Oncology, Clinical Trials, Therapy, NSCLC, Acquisition, Neoplasm, Cancer, Non-small-cell lung cancer, Messenger, NRG1, News, Pertuzumab, Epitope, PD-1, Discovery, Antibody, HER2, Lung cancer, HER3, Immunoglobulin G, Trastuzumab, Clinical trial, Immunology, NDA, ERBB2, DNA, Pharmaceutical industry

This report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape.
  • A detailed picture of the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape is provided which includes the disease overview and Non-Small-Cell Lung cancer (NSCLC) treatment guidelines.
  • The assessment part of the report embraces, in depth Non-Small-Cell Lung cancer (NSCLC) commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Non-Small-Cell Lung cancer (NSCLC) R&D.

Global Anterior Uveitis (Iritis) Drug Pipeline Research Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, Acquisition, IOP, Macrophage, News, Route, Eye, Uveitis, Discovery, Risk, Administration, Clinical trial, Immunomodulation, NDA, NCE, Pharmaceutical industry

This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Anterior Uveitis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Anterior Uveitis pipeline landscape.
  • A detailed picture of the Anterior Uveitis pipeline landscape is provided which includes the disease overview and Anterior Uveitis treatment guidelines.
  • The assessment part of the report embraces, in depth Anterior Uveitis commercial assessment and clinical assessment of the pipeline products under development.
  • Anterior Uveitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Global Psoriatic Arthritis Drug Landscape Research Report 2024: Comprehensive Insights About 20+ Companies and 25+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Therapy, Acquisition, Arthritis, Psoriasis, Psoriatic arthritis, TEM, Inflammation, Malignancy, News, Atopic dermatitis, Route, Phase II, JAK1, KCNA3, JAK3, Discovery, Cell, Bristol Myers Squibb, Multiple sclerosis, Administration, Cytokine, Rheumatoid arthritis, TYK2, Clinical trial, NDA, Lluís Companys, Immune system, JAK2, Pharmaceutical industry

This report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Psoriatic Arthritis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Psoriatic Arthritis pipeline landscape.
  • A detailed picture of the Psoriatic Arthritis pipeline landscape is provided which includes the disease overview and Psoriatic Arthritis treatment guidelines.
  • The assessment part of the report embraces, in depth Psoriatic Arthritis commercial assessment and clinical assessment of the pipeline products under development.
  • Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Adaptive Shield Now Offered Through GuidePoint Security

Retrieved on: 
Tuesday, March 5, 2024
Software, Technology, Security, Apps, Applications, Cloud, CSPM, Discovery, Risk, Software as a service, Guidepoint, Organization, Partnership

Adaptive Shield , leader in SaaS Security, today announced it will partner with GuidePoint Security , the leading cybersecurity solution provider that helps organizations make better decisions that minimize risk.

Key Points: 
  • Adaptive Shield , leader in SaaS Security, today announced it will partner with GuidePoint Security , the leading cybersecurity solution provider that helps organizations make better decisions that minimize risk.
  • As part of the Security Partner Program, Adaptive Shield’s SaaS Security Posture Management (SSPM) and Identity Threat Detection and Response (ITDR) solution is available through GuidePoint Security to address the risks associated with the usage of SaaS applications.
  • “We look forward to working with GuidePoint Security, a leader in cybersecurity strategy, as Adaptive Shield continues its global expansion to fulfill the growing demand for comprehensive SaaS security.”
    “Cyber-attack vectors are expanding across SaaS applications, challenging organizations’ security efforts with a new level of complexity,” said Justin Iwaniszyn, Director, New & Emerging Alliances, GuidePoint Security.
  • Adaptive Shield’s capabilities include:
    SaaS Security Misconfiguration Management: Monitor and manage security misconfigurations through in-depth security checks and remediation guidelines.

Incredo Announces Breakthrough in its Sugar Reduction Solution with the Launch of Incredo® Sugar G2, a Concentrated Clean-Label Offering Made of Real Sugar and Protein

Retrieved on: 
Tuesday, March 5, 2024
Food Tech, Health, FDA, Technology, Manufacturing, Fitness & Nutrition, Other Manufacturing, Multimedia, Growth, GRAS, Discovery, Natural product, Safety, GMO, Anaheim Convention Center, Taste, Hershey bar, Public key certificate

Today, food tech company Incredo , Inc. (US) has announced the launch of Incredo® Sugar G2, a concentrated version of its globally recognized and award winning sugar-based sugar reduction solution, Incredo® Sugar.

Key Points: 
  • Today, food tech company Incredo , Inc. (US) has announced the launch of Incredo® Sugar G2, a concentrated version of its globally recognized and award winning sugar-based sugar reduction solution, Incredo® Sugar.
  • The solution is the latest addition to its portfolio of innovative sugar reduction offerings for food manufacturers and CPGs.
  • View the full release here: https://www.businesswire.com/news/home/20240305181498/en/
    Incredo, Inc. (US) has announced the launch of Incredo® Sugar G2, a concentrated version of its globally recognized and award winning sugar-based sugar reduction solution.
  • A variety of companies, including several iconic food brands, are developing and testing products using Incredo Sugar and Incredo Sugar G2.

Room to Read Partners with Warner Bros. Discovery to Premiere She Creates Change, Award-Winning Film Series Promoting Gender Equality Released in Honor of International Women’s Day

Retrieved on: 
Friday, March 1, 2024
Entertainment, Film & Motion Pictures, Professional Services, Philanthropy, Books, Consumer, Other Education, DEI (Diversity, Equity and Inclusion), Fund Raising, Education, TV and Radio, Women, Nexus, Girl, SXSW, International, BAFTA, Woman, Adolescence, Multimedia, Tribeca Festival, Manchester Animation Festival, Animation, Nexus Studios, Brave, Discovery, Life, Curriculum, Series, Abominable, Girl Rising, Sound, Comics, TLC, London Short Film Festival, Music, Book, Marriage, Warner Bros. Discovery, Partnership, Film industry

Discovery for the premiere of She Creates Change , the first nonprofit-led animation and live action film project to promote gender equality through the stories of young women around the world.

Key Points: 
  • Discovery for the premiere of She Creates Change , the first nonprofit-led animation and live action film project to promote gender equality through the stories of young women around the world.
  • Discovery for the premiere of She Creates Change, the first nonprofit-led animation and live action film project to promote gender equality through the stories of young women around the world.
  • (Graphic: Business Wire)
    In celebration of International Women’s Day, the film series will premiere on Friday March 8, 15 and 22 to audiences in Asia.
  • The series will premiere as a feature length film as an official selection of the SXSW EDU Film Program on March 5, 2024.

Thunderbird Entertainment Group Reports Fiscal 2024 Q2 Results

Retrieved on: 
Thursday, February 29, 2024
Licensing (Entertainment), Online, Entertainment, TV and Radio, Podcast, Investment, News, Growth, Weather, Health, NAACP Image Awards, Intellectual property, Friends, Brunico Communications, Animation, Unicorn Island, History (American TV network), Bell Media, Gold, PBS, Blue Fox Entertainment, GLAAD Media Award, OTCQX, Pinecone & Pony, Highway Thru Hell, Partnership, Netflix, APTN, Amazon Music, Conifer cone, Thunderbird, Marvel, The Walt Disney Company, IP, Chair, Warner Bros. Discovery, Outstanding Animated Series, GPM, Crave, Atomic Cartoons, Discovery, Molly Hayes, My Little Pony, Season, Critic, Moonbug Entertainment, The Weather Channel, Boot camp

Thunderbird Entertainment Group Inc. (TSXV: TBRD, OTCQX: THBRF) (“Thunderbird” or the “Company”) today announced its Q2 2024 financial results, which ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Thunderbird Entertainment Group Inc. (TSXV: TBRD, OTCQX: THBRF) (“Thunderbird” or the “Company”) today announced its Q2 2024 financial results, which ended December 31, 2023, and provided a corporate update.
  • The Company has returned to profitability in Q2 2024, with the last half of fiscal 2024 set to be the strongest, weighted to the fourth quarter.
  • Several cost-reduction activities have been implemented and the Company expects to realize in excess of $3 million in overall cost reductions for fiscal 2024.
  • Thunderbird awards and accolades received during and subsequent to Q2 include, but are not limited to:
    Thunderbird placing No.

Global H3N2 infection Drug Pipeline Landscape Report 2024: Insights on 15+ Companies and 20+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Health, Infectious Diseases, Therapy, Acquisition, Pfizer, SARS-CoV-2, AVC, News, Glycoprotein, Moderna, NTD, RBD, FC, Discovery, COVID-19, Clinical trial, NDA, N-terminus, Immune system, Pharmaceutical industry

This report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in H3N2 infection pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in H3N2 infection pipeline landscape.
  • A detailed picture of the H3N2 infection pipeline landscape is provided which includes the disease overview and H3N2 infection treatment guidelines.
  • The assessment part of the report embraces, in depth H3N2 infection commercial assessment and clinical assessment of the pipeline products under development.
  • The companies which have their H3N2 infection drug candidates in the most advanced stage, i.e.

Helicobacter Pylori Infection Pipeline Insight Report 2024: Insights About 5+ Companies and 5+ Pipeline Drugs Featuring TenNor Therapeutics, Servatus Biopharmaceuticals, and TenNor Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, UBT, Therapy, Acquisition, Drug resistance, Limited, Helicobacter pylori, News, Discovery, Safety, Patient, Clinical trial, Infection, Pharmaceutical industry

This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Helicobacter Pylori Infection pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Helicobacter Pylori Infection pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Helicobacter Pylori Infection R&D.
  • It also analyses Helicobacter Pylori Infection therapeutic drugs key players involved in developing key drugs.
  • The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Helicobacter Pylori Infection drugs.

Sepsis Drug Pipeline Research Report 2024: Insights from 30 Companies and 35 Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Pharmaceutical, Health, Clinical Trials, Therapy, Acquisition, Blood pressure, HBV, HCV, Hepatitis B virus, Heparin, CRISPR, Infection, Escherichia coli, Melanoma, News, Cancer, Liver cancer, Discovery, Cell, Vaccine, Intensive care medicine, Adrenomedullin, ADM, COVID, Fungal infection, Patient, Protein, Clinical trial, Survival, Endothelium, NDA, Histone, Thymosin

This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape.
  • A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines.
  • This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs.